Autologous Platelet Rich Plasma Promotes the Healing of Non-Ischemic Diabetic Foot Ulcers. A Randomized Controlled Trial

Autologous Platelet-Rich Plasma in The Management of Diabetic Foot Ulcer: A Systematic Review of Randomized Controlled Trials

“…From the included studies, ulcers treated with PRP are significantly at smaller sizes at the end of the observation period except for one study. While Hossam et al (15) found that wounds treated with PRP end up smaller than control, the result was not statistically significant. This is interesting as it appears that PRP does not improve wound healing size, but it achieves wound closure at a faster rate (although the control group did eventually "catch-up").…”

Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers

“…The reported effects show great variations, ranging from wound surface area reductions and full wound closure ratios within 12–26 weeks that did not significantly differ from the control groups [ 82 , 83 , 85 , 92 ] to impressive significant wound surface area reductions from baseline of up to 98% within 80 days [ 90 ] and wound closure ratios of up to 100% within 8 weeks [ 84 ]. However, in the trials that observed superiority of the investigational treatment over standard treatment, the reported outcomes in the standard treatment (control) groups ranged up to 88% wound surface area reduction [ 90 ] and 78% full wound closure ratio [ 88 ], indicating that considerable proportions of the treated wounds have not been refractory to standard treatment (Additional file 1 : Table S15). In contrast, in the present trial we have focused on a standard treatment-refractory, extremely hard-to-heal population, which needs to be taken into account when comparing the outcomes in the present trial with those of other adjunctive treatment strategies.…”

“…A variety of other cell-based treatment strategies have been tested in controlled clinical trials for adjunctive treatment of DFUs, including autologous and allogeneic MSCs derived from bone marrow and adipose tissue [80][81][82], autologous adipose tissue and adipose-derived stromal vascular fraction cells [83,84], autologous platelet-rich plasma [83,[85][86][87][88][89][90], allogeneic platelets [91], autologous skin cells [92], skin allografts [93], and various cell-containing skin substitute products [94][95][96][97][98][99] (for a summary see Additional file 1: Table S15). The reported effects show great variations, ranging from wound surface area reductions and full wound closure ratios within 12-26 weeks that did not significantly differ from the control groups [82,83,85,92] to impressive significant wound surface area reductions from baseline of up to 98% within 80 days [90] and wound closure ratios of up to 100% within 8 weeks [84].…”

Effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds: A meta‐analysis

“…The current meta-analysis involved 19 studies recruiting 1435 subjects with diabetic foot ulcer wounds at the baseline of the studies; 723 of them were treated with platelet-rich plasma, and 712 used control. [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] The use of autologous platelet-rich plasma resulted in significantly higher complete-healed diabetic foot ulcer wounds compared with control. The use of allogeneic platelet-rich plasma resulted in significantly higher complete-healed diabetic foot ulcer wounds compared with control.…”